Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Scynexis Inc (SCYX)
Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,753
  • Shares Outstanding, K 36,517
  • Annual Sales, $ 5,090 K
  • Annual Income, $ -62,810 K
  • 60-Month Beta 2.13
  • Price/Sales 17.43
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade SCYX with:

Options Overview Details

View History
  • Implied Volatility 80.55% ( +3.10%)
  • Historical Volatility 41.91%
  • IV Percentile 14%
  • IV Rank 3.64%
  • IV High 1,475.11% on 03/20/23
  • IV Low 27.92% on 10/07/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 5,212
  • Open Int (30-Day) 5,691

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 1.03
  • Number of Estimates 1
  • High Estimate 1.03
  • Low Estimate 1.03
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +294.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +8.96%
on 06/06/23
3.00 -15.00%
on 05/09/23
-0.43 (-14.43%)
since 05/08/23
3-Month
1.15 +121.74%
on 03/20/23
3.84 -33.56%
on 04/04/23
+0.91 (+55.49%)
since 03/08/23
52-Week
1.15 +121.74%
on 03/20/23
3.84 -33.56%
on 04/04/23
+0.44 (+20.85%)
since 06/08/22

Most Recent Stories

More News
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SCYX : 2.56 (+0.79%)
GANX : 4.88 (+0.62%)
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 2.56 (+0.79%)
3 Top-Rated Companies to Buy Today

Amid the Fed’s monetary policy tightening and the recent financial sector turmoil, fears of an economic slowdown have soared, which in turn induced market volatility. Given this backdrop, quality stocks...

CMCSA : 40.32 (-0.07%)
GSK : 34.55 (+0.55%)
MDT : 83.18 (+0.35%)
SCYX : 2.56 (+0.79%)
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis....

GSK : 34.55 (+0.55%)
NVO : 159.31 (+1.13%)
SCYX : 2.56 (+0.79%)
JSPR : 1.6000 (unch)
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions

SCYX : 2.56 (+0.79%)
GSK : 34.55 (+0.55%)
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SCYX : 2.56 (+0.79%)
CASI : 2.56 (+4.36%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 2.56 (+0.79%)
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

FHTX : 7.88 (-0.38%)
SCYX : 2.56 (+0.79%)
Pacira (PCRX) Lags Q3 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PCRX : 37.41 (-0.35%)
SCYX : 2.56 (+0.79%)
Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SCYX : 2.56 (+0.79%)
IONS : 40.98 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 2.76
2nd Resistance Point 2.65
1st Resistance Point 2.60
Last Price 2.56
1st Support Level 2.44
2nd Support Level 2.33
3rd Support Level 2.28

See More

52-Week High 3.84
Fibonacci 61.8% 2.81
Last Price 2.56
Fibonacci 50% 2.49
Fibonacci 38.2% 2.18
52-Week Low 1.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar